Format

Send to

Choose Destination
Annu Rev Med. 2016;67:11-28. doi: 10.1146/annurev-med-062913-051343. Epub 2015 Oct 14.

The PI3K/AKT Pathway as a Target for Cancer Treatment.

Author information

1
Departments of Medicine and Cancer Biology; Breast Cancer Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine, Nashville, Tennessee 37232; email: ingrid.mayer@vanderbilt.edu , carlos.arteaga@vanderbilt.edu.

Abstract

Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.

KEYWORDS:

breast cancer; lymphoproliferative disorders; mammalian target of rapamycin (mTOR); mutation; pathway inhibitors; phosphoinositide 3-kinase (PI3K)/AKT

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center